Thymmune is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases. Thymmune is based in Cambridge, MA. For more information, visit www.thymmune.com.
Location: United States, Massachusetts, Cambridge
Employees: 1-10
Total raised: $7M
Founded date: 2019
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.03.2023 | Seed | $7M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 02.03.2023 | Thymmune Secures $7 Million in Seed Financing to Develop Thy... | Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore ... | aithority.... |
| 01.03.2023 | Thymmune Secures $7M in Seed Financing | CAMBRIDGE,MA,Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therap... | vcnewsdail... |
| 01.03.2023 | Thymmune Raises $7M in Seed Financing | Thymmune Therapeutics, a Cambridge, MA-based biotechnology company developing scalable thymic cell t... | finsmes.co... |
| - | Thymmune Therapeutics | “Thymmune Therapeutics” | fastfounde... |